Literature DB >> 3546378

Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms.

N S Schwartz, W E Clutter, S D Shah, P E Cryer.   

Abstract

To define glycemic thresholds for activation of glucose counterregulatory systems and for symptoms of hypoglycemia, we measured these during stepped reductions in the plasma glucose concentration (in six 10-mg/dl hourly steps) from 90 to 40 mg/dl under hyperinsulinemic clamp conditions, and compared these with the same measurements during euglycemia (90 mg/dl) under the same conditions over 6 h in 10 normal humans. Arterialized venous plasma glucose concentrations were used to calculate glycemic thresholds of 69 +/- 2 mg/dl for epinephrine secretion, 68 +/- 2 mg/dl for glucagon secretion, 66 +/- 2 mg/dl for growth hormone secretion, and 58 +/- 3 mg/dl for cortisol secretion. In contrast, the glycemic threshold for symptoms was 53 +/- 2 mg/dl, significantly lower than the thresholds for epinephrine (P less than 0.001), glucagon (P less than 0.001), and growth hormone (P less than 0.01) secretion. Thus, the glycemic thresholds for activation of glucose counterregulatory systems during decrements in plasma glucose lie within or just below the physiologic plasma glucose concentration range, and are substantially higher than the threshold for hypoglycemic symptoms in normal humans. These findings provide further support for the concept that glucose counterregulatory systems are involved in the prevention, as well as the correction, of hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3546378      PMCID: PMC424197          DOI: 10.1172/JCI112884

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Role of hepatic autoregulation in defense against hypoglycemia in humans.

Authors:  G Bolli; P De Feo; G Perriello; S De Cosmo; M Ventura; P Campbell; P Brunetti; J E Gerich
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

2.  Enhanced glycemic responsiveness to epinephrine in insulin-dependent diabetes mellitus is the result of the inability to secrete insulin. Augmented insulin secretion normally limits the glycemic, but not the lipolytic or ketogenic, response to epinephrine in humans.

Authors:  M A Berk; W E Clutter; D Skor; S D Shah; R P Gingerich; C A Parvin; P E Cryer
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

3.  The human sympathochromaffin system.

Authors:  S D Shah; T F Tse; W E Clutter; P E Cryer
Journal:  Am J Physiol       Date:  1984-09

Review 4.  Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus.

Authors:  P E Cryer; J E Gerich
Journal:  N Engl J Med       Date:  1985-07-25       Impact factor: 91.245

5.  The role of autoregulation of the hepatic glucose production in man. Response to a physiologic decrement in plasma glucose.

Authors:  I Hansen; R Firth; M Haymond; P Cryer; R Rizza
Journal:  Diabetes       Date:  1986-02       Impact factor: 9.461

6.  External and internal standards in the single-isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine.

Authors:  S D Shah; W E Clutter; P E Cryer
Journal:  J Lab Clin Med       Date:  1985-12

7.  Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man.

Authors:  S G Rosen; W E Clutter; M A Berk; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

8.  Insulin and C-peptide levels after oral and intravenous glucose. Contribution of enteroinsular axis to insulin secretion.

Authors:  S M Hampton; L M Morgan; J A Tredger; R Cramb; V Marks
Journal:  Diabetes       Date:  1986-05       Impact factor: 9.461

9.  Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion.

Authors:  T F Tse; W E Clutter; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

10.  Neuroendocrine responses to glucose ingestion in man. Specificity, temporal relationships, and quantitative aspects.

Authors:  T F Tse; W E Clutter; S D Shah; J P Miller; P E Cryer
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

View more
  72 in total

1.  Epinephrine deficiency results in intact glucose counter-regulation, severe hepatic steatosis and possible defective autophagy in fasting mice.

Authors:  Rana I Sharara-Chami; Yingjiang Zhou; Steven Ebert; Karel Pacak; Umut Ozcan; Joseph A Majzoub
Journal:  Int J Biochem Cell Biol       Date:  2012-03-03       Impact factor: 5.085

2.  The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects.

Authors:  C Berne; J Fagius; T Pollare; P Hjemdahl
Journal:  Diabetologia       Date:  1992-09       Impact factor: 10.122

3.  Adaptation to mild hypoglycaemia in normal subjects despite sustained increases in counter-regulatory hormones.

Authors:  D Kerr; I A Macdonald; R B Tattersall
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

Review 4.  Neuroendocrine responses to hypoglycemia.

Authors:  Nolawit Tesfaye; Elizabeth R Seaquist
Journal:  Ann N Y Acad Sci       Date:  2010-10-29       Impact factor: 5.691

5.  The effects of carbohydrate supplementation during the second of two prolonged cycling bouts on immunoendocrine responses.

Authors:  Tzai-Li Li; Michael Gleeson
Journal:  Eur J Appl Physiol       Date:  2005-09-30       Impact factor: 3.078

6.  DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice.

Authors:  Siri Malmgren; Bo Ahrén
Journal:  Diabetologia       Date:  2015-02-09       Impact factor: 10.122

Review 7.  Disorders of glucose metabolism-post mortem analyses in forensic cases: part I.

Authors:  Cornelius Hess; Frank Musshoff; Burkhard Madea
Journal:  Int J Legal Med       Date:  2010-09-29       Impact factor: 2.686

8.  Alterations of immunoendocrine responses during the recovery period after acute prolonged cycling.

Authors:  Tzai-Li Li; Pei-Yun Cheng
Journal:  Eur J Appl Physiol       Date:  2007-08-01       Impact factor: 3.078

9.  Defining hypoglycaemia: what level has clinical relevance?

Authors:  B M Frier
Journal:  Diabetologia       Date:  2008-11-19       Impact factor: 10.122

10.  Acidosis mediates recurrent hypoglycemia-induced increase in ischemic brain injury in treated diabetic rats.

Authors:  Ashish K Rehni; Vibha Shukla; Miguel A Perez-Pinzon; Kunjan R Dave
Journal:  Neuropharmacology       Date:  2018-03-15       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.